Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors | MicrobiomeTrials← Back to trialsNCT03333616
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2017-12-28Est. Completion: 2026-12-30
Enrollment target: 100 participants Locations- University of California, San Diego Moores Cancer Center, La Jolla, California, United States
- Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- MD Anderson Cancer Center, Houston, Texas, United States
Other microbiome trials you might be interested in
Muscle Invasive Bladder Urothelial CarcinomaMuscle Invasive Renal Pelvis Urothelial CarcinomaMuscle Invasive Ureter Urothelial CarcinomaMuscle Invasive Urethral Urothelial CarcinomaStage II Bladder Urothelial Carcinoma AJCC v6 and v7Stage III Bladder Urothelial Carcinoma AJCC v6 and v7Stage IV Bladder Urothelial Carcinoma AJCC v7
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or uret…
Phoenix, United StatesEst. completion Sep 2, 2030
Recruiting
In this exploratory, single-arm, nonrandomized trial, the impact of the preoperative utilization of the glucagon-like pe…
Gilbert, United StatesEst. completion May 2028
AIDS-related LymphomaHIV Infection
The goal of this clinical trial is to evaluate the efficacy and safety of different antiretroviral therapy (ART) strateg…
Shanghai, ChinaEst. completion Jul 2028